Details of the Drug Combination

General Information of Drug Combination (ID: DC7P5T6)

Drug Combination Name

MK-3102

Indication

Disease Entry	Status	REF
Diabetes Mellitus	Phase 3	[1]

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of MK-3102

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 3	[2]

MK-3102 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Modulator	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01814748) A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?8 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8402).
3	Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.